Showing 3271-3280 of 5773 results for "".
- FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platformhttps://modernod.com/news/fda-grants-breakthrough-device-status-to-tokus-patented-cardiovascular-risk-ai-clair-platform/2481934/Toku announced that the FDA has granted Breakthrough Device designation to its patented CLAiR technology. According to Toku, the CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive
- ADA and Genentech Launch Campaign to Raise Awareness and Address Inequity in Diabetes-Related Eye Diseasehttps://modernod.com/news/ada-and-genentech-launch-campaign-to-raise-awareness-and-address-inequity-in-diabetes-related-eye-disease/2481933/The American Diabetes Association (ADA) and Genentech, anchor partner of the ADA’s 'Health Equity Now' program, launched the 'Eye Pledge to Fight Diabetes.' This program encourages people with diabetes and their loved ones to get an annual eye exam, which have
- Alcon Showcases Cloud-Based Planning and Digital Technologies During AAO 2023https://modernod.com/news/alcon-showcases-cloud-based-planning-and-digital-technologies-during-aao-2023/2481930/At the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting in San Francisco, Alcon will provide connected equipment ecosystems via its digital innovation technology. Ophthalmologists, surgical staff, researchers, and industry leaders will have the opportunity to ex
- AbbVie Enters into Option Agreement with Aldeyra Therapeutics for License to Develop and Commercialize Reproxalaphttps://modernod.com/news/abbvie-enters-into-option-agreement-with-aldeyra-therapeutics-for-license-to-develop-and-commercialize-reproxalap/2481929/Aldeyra Therapeutics announced that it has entered into an exclusive option agreement with AbbVie in which AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the US, and an exclusive license to develop, manufacture, and comme
- Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDhttps://modernod.com/news/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-first-pivotal-clinical-trial-of-otx-tki-in-wet-amd/2481928/Ocular Therapeutix announced it has received written agreement regarding the overall design from the FDA under a Special Protocol Assessment (SPA) for the company’s ongoing pivotal phase 3 clinical trial for Axpaxli (axitinib intravitreal implant), for the treatment of wet ag
- Okogen Initiates Phase 2b Clinical Trial for Acute Infectious Conjunctivitishttps://modernod.com/news/okogen-initiates-phase-2b-clinical-trial-for-acute-infectious-conjunctivitis/2481926/Okogen announced the initiation of a phase 2b clinical trial evaluating OKG-0303 for acute infectious conjunctivitis (pink eye) to be conducted in India. Additionally, as part of the corporate reorganization, Bradford Conlan has been appointed Executive Chairman; and Joshua Moriarty, Okogen&
- FDA Approves OnPoint Vision’s IDE Application to Begin Phase 1 of IOPCL Magnifierhttps://modernod.com/news/fda-approves-onpoint-visions-ide-application-to-begin-phase-1-of-iopcl-magnifier/2481925/OnPoint Vision announced the FDA approval of their investigational device exemption (IDE) application to begin phase 1 of their pivotal clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with
- SpyGlass Pharma Initiates Phase 1/2 Clinical Trial of its Intraocular Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/SpyGlass Pharma announced the initiation of a phase 12 clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass
- ViaLase Completes Enrollment for the VIA-002 Trial of the ViaLase Laser to Treat Primary Open Angle Glaucomahttps://modernod.com/news/vialase-completes-enrollment-for-the-via-002-trial-of-the-vialase-laser-to-treat-primary-open-angle-glaucoma/2481921/ViaLase announced it has completed enrollment of VIA-002, the company's pivotal trial of the ViaLase Laser to treat adult patients with primary open angle glaucoma (POAG). The ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image
- Bausch + Lomb Launches SeeNa Optical Biometry and Topography System in the United Stateshttps://modernod.com/news/bausch-lomb-launches-seena-optical-biometry-and-topography-system-in-the-united-states/2481920/Bausch + Lomb announced the U.S. launch of SeeNa, an ophthalmic diagnostic system for refractive cataract patients that is fully integrated with Bausch + Lomb’s